236 related articles for article (PubMed ID: 25187879)
1. CETP inhibitors and cardiovascular disease: Time to think again.
Miller NE
F1000Res; 2014; 3():124. PubMed ID: 25187879
[TBL] [Abstract][Full Text] [Related]
2. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
3. Cholesteryl ester transfer protein inhibitors in precision medicine.
Su X; Li G; Deng Y; Chang D
Clin Chim Acta; 2020 Nov; 510():733-740. PubMed ID: 32941836
[TBL] [Abstract][Full Text] [Related]
4. Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia.
Poliakova T; Wellington CL
Mol Neurodegener; 2023 Nov; 18(1):86. PubMed ID: 37974180
[TBL] [Abstract][Full Text] [Related]
5. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.
Vasan RS; Pencina MJ; Robins SJ; Zachariah JP; Kaur G; D'Agostino RB; Ordovas JM
Circulation; 2009 Dec; 120(24):2414-20. PubMed ID: 19948972
[TBL] [Abstract][Full Text] [Related]
6. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
[TBL] [Abstract][Full Text] [Related]
8. Structure-based mechanism and inhibition of cholesteryl ester transfer protein.
Xue H; Zhang M; Liu J; Wang J; Ren G
Curr Atheroscler Rep; 2023 Apr; 25(4):155-166. PubMed ID: 36881278
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
10. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Sirtori CR
Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
[TBL] [Abstract][Full Text] [Related]
11. CETP inhibition in cardiovascular risk management: a critical appraisal.
Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
[TBL] [Abstract][Full Text] [Related]
12. Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults.
Millwood IY; Bennett DA; Holmes MV; Boxall R; Guo Y; Bian Z; Yang L; Sansome S; Chen Y; Du H; Yu C; Hacker A; Reilly DF; Tan Y; Hill MR; Chen J; Peto R; Shen H; Collins R; Clarke R; Li L; Walters RG; Chen Z;
JAMA Cardiol; 2018 Jan; 3(1):34-43. PubMed ID: 29141072
[TBL] [Abstract][Full Text] [Related]
13. Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels.
Scharnagl H; Heuschneider C; Sailer S; Kleber ME; März W; Ritsch A
Eur J Clin Invest; 2014 Apr; 44(4):395-401. PubMed ID: 24467215
[TBL] [Abstract][Full Text] [Related]
14. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
Miyares MA; Davis K
Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
[TBL] [Abstract][Full Text] [Related]
15. Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population.
Nordestgaard LT; Christoffersen M; Lauridsen BK; Afzal S; Nordestgaard BG; Frikke-Schmidt R; Tybjærg-Hansen A
JAMA Cardiol; 2022 Jan; 7(1):55-64. PubMed ID: 34613338
[TBL] [Abstract][Full Text] [Related]
16. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
[TBL] [Abstract][Full Text] [Related]
17. A novel cholesteryl ester transfer protein promoter polymorphism (-971G/A) associated with plasma high-density lipoprotein cholesterol levels. Interaction with the TaqIB and -629C/A polymorphisms.
Le Goff W; Guerin M; Nicaud V; Dachet C; Luc G; Arveiler D; Ruidavets JB; Evans A; Kee F; Morrison C; Chapman MJ; Thillet J
Atherosclerosis; 2002 Apr; 161(2):269-79. PubMed ID: 11888509
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR
Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395
[TBL] [Abstract][Full Text] [Related]
19. CETP Inhibition: Past Failures and Future Hopes.
Kosmas CE; DeJesus E; Rosario D; Vittorio TJ
Clin Med Insights Cardiol; 2016; 10():37-42. PubMed ID: 26997876
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.
Nelson AJ; Sniderman AD; Ditmarsch M; Dicklin MR; Nicholls SJ; Davidson MH; Kastelein JJP
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
